AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

12,118.00p
   
  • Change Today:
    -54.00p
  • 52 Week High: 12,370.00p
  • 52 Week Low: 9,501.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.24m
  • Volume: 239,244
  • Market Cap: £187,858m
  • RiskGrade: 123

AstraZeneca, Sanofi infant respiratory treatment gets US approval

By Frank Prenesti

Date: Tuesday 18 Jul 2023

LONDON (ShareCast) - (Sharecast News) - AstraZeneca and Sanofi's Beyfortus drug has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants, the two companies said on Tuesday.




The treatment is given to those born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Beyfortus will be available in the US ahead of the upcoming 2023-2024 RSV season, they added.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 12,118.00p
Change Today -54.00p
% Change -0.44 %
52 Week High 12,370.00p
52 Week Low 9,501.00p
Volume 239,244
Shares Issued 1,550.24m
Market Cap £187,858m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.48% below the market average92.48% below the market average92.48% below the market average92.48% below the market average92.48% below the market average
92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average
Price Trend
59.08% above the market average59.08% above the market average59.08% above the market average59.08% above the market average59.08% above the market average
66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average
Income
91.19% below the market average91.19% below the market average91.19% below the market average91.19% below the market average91.19% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
82.60% above the market average82.60% above the market average82.60% above the market average82.60% above the market average82.60% above the market average
94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average

What The Brokers Say

Strong Buy 8
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 22-Feb-24 10-Aug-23
Paid 25-Mar-24 11-Sep-23
Amount 197.00¢ 93.00¢

Trades for 16-May-2024

Time Volume / Share Price
11:31 3 @ 12,118.00p
11:30 0 @ 12,120.00p
11:30 13 @ 12,120.00p
11:30 22 @ 12,120.00p
11:30 92 @ 12,121.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page